低剂量现在素对改善动脉硬度的影响:试点研究
Yuqi Guan1,2, Yucong Zhang1,2, Liangkai Chen3,4
1Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Journal of cellular and molecular medicine
|July 23, 2024
概括
低剂量泰拉索因在降低动脉硬性方面表现有前途,这是动脉衰老的关键指标. 这项试点研究发现,许多患者的血管衰老标志物有显著改善,这表明现在osin.
科学领域:
- 心血管医学 心血管医学
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉硬是死亡率的重要预测因素,也是血管衰老的标志.
- 促进血管健康衰老对于长寿和生活质量至关重要.
研究的目的:
- 为了研究低剂量泰拉佐辛对40岁以上患者动脉硬度的影响.
- 评估泰拉索因作为治疗策略,用于控制血管衰老的潜力.
主要方法:
- 试点研究涉及患有动脉硬度升高的患者 (臂脉冲波速度≥1400厘米/秒).
- 现在osin的剂量为0.5和1.0毫克/天,每3个月进行一次评估.
- 倾向分数匹配 (PSM) 用于比较1年的 Terazosin 用户与无 Terazosin 控制组.
主要成果:
- 在12个月内,在48.6%-59.3%的患者中观察到动脉硬的显著改善 (baPWV减少≥5%).
- 较高的基线baPWV和高血压与对Terazosin不反应的风险降低有关.
- 线性回归证实了Tarazosin与1年随访后降低baPWV的相关性 (β = -165.16,p < 0.001).
结论:
- 低剂量泰拉索因在改善动脉硬性和打击血管衰老方面表现出潜在的潜力.
- 这些发现支持通过随机临床试验进行进一步的研究,以证实 Terazosin 的疗效.
- 现在osin可能为管理与年龄相关的动脉硬化提供一种新的治疗方法.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
683
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
683
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
01:23Antihypertensive Drugs: Vasodilators
495
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
495
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
589
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
589
01:25Antihypertensive Drugs: Direct Renin Inhibitors
528
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
528
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
142
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
142